Dear LabPulse.com member,
The world in vitro diagnostics (IVD) market will reach $127.4 billion dollars in 2022.
That's the finding from a market research report published by Kalorama Information, The Worldwide Market for In Vitro Diagnostics, 15th Edition.
COVID-19 testing is expected to contribute $32.6 billion to the IVD market this year but the bulk of the market revenues, $94.8 billion, will be generated by non-COVID-19 IVD tests, the report noted.
Meanwhile, through a broad survey of participants in a clinical study, researchers recently shed light on an issue of some debate within the IVD industry. Based on the study results, they determined that rapid antigen tests are accurate for detecting variants of SARS-CoV-2, such as pre-Delta, Delta, and Omicron variants.
Meanwhile, the diagnosis of long COVID has received less attention than testing for SARS-CoV-2 variants, but according to the Centers for Disease Control and Prevention, the range of symptoms for long COVID make it difficult to ascertain whether the symptoms result from the virus or other health problems.
Long COVID's diagnosis and treatment are driving up health costs. Based on a review of claims information, employers spend an average of $2,654.67 per employee diagnosed with long COVID, Nomi Health said this week.
This past week, we reported on two studies related to the use of genetic tests to improve cardiac care. A polygenic risk score previously successful in predicting coronary artery disease can also identify those patients at highest risk for developing sudden cardiac death, according to research published recently in the Journal of the American College of Cardiology.
Meanwhile, combined genetic testing for patients with a suspected genetic cardiomyopathy or arrhythmia can diagnose patients who would have been missed if genetic testing had been restricted to a suspected disease subtype, according to research recently published in JAMA Cardiology.
In a study published recently in Science Advances, University of Colorado researchers found that plasma cell-free DNA (cfDNA) contains high resolution, genome-wide binding estrogen receptors (ER) and FOXA1 profiles for breast cancer. As a result, the researchers have developed a blood-based cell-free DNA method that they believe could simplify the monitoring of breast cancer progression.
On Tuesday, Thermo Fisher Scientific announced it has launched its CE-IVD (IVDD) Oncomine Dx Express Test and Oncomine Reporter Dx software for clinical labs. Using targeted NGS technology, the Oncomine Dx Express Test delivers clinically relevant tumor mutation profiling in 24 hours to aid healthcare professionals in therapy management of cancer patients in accordance with professional guidelines, Thermo Fisher said.